Skip to main content

Table 9 Multivariate logistic regression analysis of the relationship between treatments received by the patient and generalized anxiety disorder

From: The psychological impact of inflammatory bowel disease as regards anxiety and depression: a single-center study

  Generalized anxiety disorder OR (CI 95%) Test of significance
No (N = 66) Yes (N = 39)
N (%) N (%) Value p-value Sig.
Oral mesalamine No 18 (27.27%) 13 (33.33%) 0.75 (0.32–1.77) X2 = 0.433 0.511C NS
Yes 48 (72.73%) 26 (66.67%)
Topical mesalamine No 63 (95.45%) 38 (97.44%) 0.55 (0.06–5.51)   1.00F NS
Yes 3 (4.55%) 1 (2.56%)
Oral steroids No 43 (65.15%) 26 (66.67%) 0.94 (0.41–2.16) X2 = 0.025 0.874C NS
Yes 23 (34.85%) 13 (33.33%)
Topical steroids No 64 (96.97%) 39 (100%)    0.529F NS
Yes 2 (3.03%) 0 (0%)
Azathioprine No 27 (40.91%) 8 (20.51%) 2.68 (1.07–6.73) X2 = 4.589 0.032C S
Yes 39 (59.09%) 31 (79.49%)
Biological therapy No 55 (83.33%) 29 (74.36%) 1.72 (0.66–4.54) X2 = 1.234 0.267C NS
Yes 11 (16.67%) 10 (25.64%)
Type remicade 1–Humera 2 No 59 (89.39%) 32 (82.05%) 1.84 (0.59–5.72) X2 = 1.144 0.285C NS
Yes 7 (10.61%) 7 (17.95%)
Surgical intervention No 61 (92.42%) 37 (94.87%) 0.66 (0.12–3.57)   1.00F NS
Yes 5 (7.58%) 2 (5.13%)
  1. CChi-square test of significance (X2, chi-square test value). FMonte-Carlo Fisher’s exact test of significance